Do pharma HCP portals still matter in a world of AI overviews?

In a world where AI overviews answer the question before an HCP ever reaches your website, the visitors who do click through are not a diminished audience. They are a self-selected one. They came because the AI answer wasn't enough. That is not a problem to solve. That is an opportunity most pharma organizations are not yet equipped to capture.

Executive summary

Pharma HCP portals are being filtered. AI overviews intercept an increasing share of healthcare professionals' searches. The visitors who still click through to the portal are fewer, but meaningfully more qualified.

The volume loss is real. The value loss is not.

This article examines what the zero-click era actually means for the HCP digital customer journey. Where is the real drop-off is happening? What can pharma leaders do to reassign a portal experience built for the HCP who arrives in 2026?

Key findings

• According to Ahrefs, click-through rates from search have dropped by up to 58% since 2025

• HCPs who arrive via AI-cited links tend to be more purposeful

• Content relevance and login friction are the friction points pharma digital leaders most consistently identify as priorities for improvement

• Pharma HCP portals face a structural disadvantage in LLM training data due to gating and perceived neutrality concerns

• The portal's role is shifting from traffic destination to source of truth

What does the zero-click era actually means for pharma HCP portals?

For most of the last decade, pharma digital teams measured portal success in sessions and pageviews. Traffic was the proxy for relevance. The more HCPs arrived, the better the strategy was assumed to be working.

That model is breaking down because the search behavior that fed them has fundamentally changed.

AI overviews, now embedded across Google, ChatGPT, Perplexity, and an expanding range of clinical decision tools, are answering a growing share of the questions HCPs previously had to visit a website to resolve.

Treatment protocols, dosing guidance, mechanism-of-action summaries, and drug interaction checks. The content that once drove meaningful portal traffic is increasingly being surfaced, synthesized, and delivered before a single click occurs.

How AI overviews are intercepting the HCP digital customer journey

The classic HCP digital customer journey assumed a linear path. A healthcare professional encounters a clinical question, searches for information, finds a relevant result, clicks through, and engages with portal content. Each step was an opportunity to inform, to build familiarity, to prompt action.

AI overviews have collapsed the middle of that journey. The search, the result, and a version of the answer now happen in a single moment, before any portal is involved. What remains is a more compressed, higher-stakes interaction. An HCP who has already received a synthesized answer, and is now deciding whether it is sufficient or whether something is missing.

For pharma, this changes the question from "how do we get HCPs to our portal?" to "what does our portal offer that an AI overview cannot?"

The answer requires a clear-eyed view of where genuine value lives.

Why pharma was never fully dependent on search, and what that means now

Unlike consumer health or general medical content, many pharma HCP portals were never primarily built on organic search traffic. Compliance constraints around promotional content in search results led many organizations to rely instead on direct channels to drive HCPs into gated environments.

For these organizations, the zero-click shift is less of an emergency and more of a structural clarification. Search was never the main door. What AI overviews are doing is revealing how dependent the wider digital health ecosystem has become on a channel that pharma largely bypassed.

The implication is significant: pharma digital leaders are, in some respects, better positioned than their counterparts in other sectors to adapt, provided they redirect their attention from traffic recovery to experience quality. The HCPs still arriving deserve a journey worth completing.

The zero-click paradox: fewer visitors, higher-quality engagement

As organic traffic to pharma HCP portals has declined, conversion rates have risen. HCPs completing video modules, downloading clinical materials, requesting samples, progressing through multi-step educational journeys: the proportion of visitors taking meaningful action is going up, even as the total number of visitors goes down.

This is a structural shift in who is arriving and why.

What this tells us about HCP intent in 2026

The HCP who reaches a pharma portal today has cleared a higher bar than their 2022 equivalent. They did not stumble onto the page from a generic search. They received an AI-generated overview, found it insufficient for their purposes, identified a specific gap, and made a deliberate decision to go further.

That deliberateness is what shows up in conversion metrics. These are not passive browsers. They are purposeful visitors with a defined need and the motivation to act on it.

The goal has become to be findable by the right HCP at the moment their AI overview leaves them wanting more, and then to deliver, immediately and without friction, exactly what they came for.

The three friction points breaking the HCP digital customer journey

If the HCPs arriving at pharma portals today are more qualified and more purposeful than ever before, the question that follows is uncomfortable: why are so many of them still leaving without getting what they came for?

Usually, the answer is access. More specifically, the pain points that stand between an HCP with a defined need and the information that meets it.

Three friction points emerge with striking consistency. They are not new problems. What is new is the cost of leaving them unresolved. In a zero-click environment, where every portal visit represents a deliberate decision by a high-intent HCP, each unnecessary obstacle carries a disproportionate penalty. 

And the gap between a frictionless customer experience and the reality of most pharma portals has never been more costly.

Friction point 1: landing pages that don’t match what HCPs were searching for

An HCP follows an AI-cited link expecting to land on content directly relevant to the query that prompted their search. What they frequently encounter instead is a generic homepage with no clear path to the specific information they were promised.

This mismatch between search intent and landing experience is the single most commonly cited priority for improvement among pharma digital teams. And it is particularly damaging in the zero-click era for a specific reason: the HCP arriving via an AI-cited link has already had their expectation set. The AI overview implicitly told them that this source has the answer. A generic homepage tells them it does not.

The drop-off at this point is rapid. HCPs are time-poor by definition. A portal that forces them to navigate from a homepage to the content they need is asking them to do work they are not obligated to do, and in most cases, they will not.

The fix is about rethinking the link layer. Deep links that route directly to relevant content, URL structures that reflect clinical intent, and landing pages optimized for the specific queries that are driving AI-cited traffic are all more immediately impactful than any homepage redesign.

Friction point 2: login and registration barriers

The HCP portal user experience breaks down most visibly at authentication. HCPs are asked to create accounts, remember credentials, verify their professional status, and wait for confirmation: a sequence designed around the data needs of the pharmaceutical company rather than the time constraints of the clinician.

The HCP arriving via an AI-cited link followed a source reference. They have thirty seconds of attention and a specific question. A multi-step registration flow is not a minor inconvenience at this point; it is a full stop.

The honest assessment is that no single solution works across all markets, all HCP segments, and all compliance frameworks simultaneously. What is clear is that the status quo, the mandatory account creation with email confirmation, is the source of pharma HCP login friction that no amount of content optimization can compensate for.

Friction point 3: waiting for account confirmation when the clinical questions can’t wait

From a regulatory and compliance standpoint, this verification step is often non-negotiable. The content behind the gate is promotional, clinical, or both, and the legal framework in most markets requires that it be accessible only to verified professionals.

The problem is timing. An HCP who registers at 11 pm after a ward round, needs clinical information by the next morning, and receives a verification email at 9 am the following day has already found the answer elsewhere. The portal has not served them. It has simply collected their email address.

The solutions here are less about removing verification and more about compressing it. Integration with existing professional registries, such as prescriber databases, medical council records, and national HCP identification systems, can enable real-time or near-real-time verification without manual review. OTP systems tied to registered mobile numbers achieve a similar outcome in markets with mobile-based HCP databases.

The underlying principle is the same across all three friction points: the HCP digital customer journey must be redesigned around the clinician's time constraints and level of intent, rather than the organization's data and compliance preferences. In the zero-click era, pharma portals have one opportunity to justify the click. Friction at any stage of that journey is the risk that opportunity is not taken.

Should pharma HCP portals try to rank in AI overviews — or go where HCPs already are?

Accepting that portal traffic will decline is one thing. Deciding what to do about visibility in the systems now intercepting that traffic is another, and it is where pharma digital strategy is most actively, and most productively, divided.

The dominant instinct is to treat AI overviews as a new SEO problem: understand how LLMs surface content, optimize accordingly, and recover the visibility that Google's traditional blue links once provided. It is a reasonable instinct. It is also likely to produce disappointing results for many pharma companies.

The reason is structural, and it has nothing to do with content quality.

Why pharma HCP sites often rank lower in LLM training data and what to do about it

Large language models (the systems powering AI overviews across Google, ChatGPT, Perplexity, and their equivalents) are trained and retrieval-augmented on data that skews heavily toward open, high-authority, neutral sources. Academic journals, medical reference databases, government health agencies, established clinical guidelines bodies. These are the sources LLMs weight most heavily because they have the broadest citation networks, the longest track records of accuracy, and no commercial relationship with the content they publish.

Pharma HCP portals, by their nature, sit outside this ecosystem. Their content is gated, invisible to crawlers and therefore absent from training data. Where ungated content exists, it is typically promotional in framing, brand-affiliated, or both. 

And the pharmaceutical industry's historical relationship with clinical information, shaped by legitimate regulatory requirements but also by genuine episodes of selective data presentation, has left a residue of concern about neutrality that LLMs appear to reflect in how they weight pharma-owned sources.

The case for the portal as a source of truth, not a traffic destination

A pharma HCP portal cannot easily become a high-authority neutral source in the eyes of an LLM. It can, however, become the definitive destination for depth that no neutral source can provide: full prescribing information, proprietary clinical trial data, disease-specific educational programs, personalized content based on therapeutic area and geography, and direct access to medical information teams.

This reframing shifts the portal's success metric away from search visibility and toward conversion depth: not how many HCPs arrive, but how fully the portal serves those who do. It also changes the investment calculus: less resource toward discoverability, more toward the experience that justifies the visit.

The third-party authority play: publishing where doctors already read

The complementary strategy, and for LLM visibility specifically, arguably the more immediately effective one, is to publish on the platforms that LLMs already trust.

Peer-reviewed journals, established medical education platforms, therapeutic area society websites, and high-authority clinical reference tools occupy a fundamentally different position in LLM training data than pharma-owned portals. They are open, heavily cited, institutionally credible, and actively indexed. Content published on these platforms does not face the neutrality discount that pharma-branded portals carry.

For pharma organizations, this means treating third-party publication as a core component of HCP digital strategy. Therapeutic information published in collaboration with the European Medical Journal, clinical education content hosted on established CME platforms, disease awareness material developed with patient advocacy organizations: these are visibility plays within the systems that now mediate the first stage of the HCP digital customer journey.

The practical implication is a shift in how pharma digital and medical affairs teams collaborate. Content strategy can no longer sit entirely within owned digital channels. The question is not only "what does our portal contain?" but "where does authoritative content about our therapy area live — and are we contributing to it?"

Conclusion: do pharma HCP portals still matter?

Yes.

But not in the way most pharma digital strategies currently assume.

Building a frictionless customer journey is a commercial imperative that determines whether a purposeful HCP becomes an engaged one.

The portal that matters in 2026 is a high-value destination for a smaller, more purposeful audience. It’s the place an HCP goes when an AI overview was not enough. It is the point at which that journey reaches its highest value, not the beginning of it.

The question pharma digital leaders should be sitting with is not "how do we get our traffic back?" Traffic, in the traditional sense, is not coming back, but the fraction that does return is more valuable than what was lost. 

The question is: "When the right HCP arrives, are we ready for them?"